MainMarket in Brief

Vedomosti

Doctis Buys 51% of Ipharma to Digitize Clinical Trials

December 21, 2021, 10:55 (UTC+3)|
169

The telemedicine service Doctis acquired a controlling stake (51%) in the contract research company Ipharma. The cost of the transaction was not disclosed.

The companies jointly intend to develop a platform for the digitalization of clinical trials (CI) of drugs. It also implies the creation of a mobile application for CI participants. With its help, they will enter data on the body's reactions to the drugs under study. The prototype of the platform is expected to be ready in the middle of next year.


Product cards

Doctis, Ipharma


Doctis's plans to acquire a stake in Ifarma to enter the clinical trials market were reported in November 2021. It was also revealed that the processing of the obtained data, their layout, comparison of research results will be carried out using artificial intelligence.

Original (in Russian)

Subject:

#deals

Companies:

#Doctis#Ipharma

Share:

Learn more about Moscow IT Market by subscribing to our newsletters

By clicking the button you agree to Privacy Policy

Unless otherwise stated, the content is available under Creative Commons BY 4.0 license

Supported by the Moscow Government